GSK plc announced that the US FDA has accepted gepotidacin for priority review as an oral treatment for uncomplicated gonorrhoea, an event occurring on August 11, 2025, based on positive phase III trial data showing a 92.6% success rate. This approval could provide a new treatment option as over 600,000 gonorrhoea cases were reported in the US in 2023, emphasizing the urgent need for alternatives to injectable treatments.